NCT03347292 - Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

December 17, 2020

Study Completion Date

September 6, 2022

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Regorafenib(Stivarga, BAY73-4506)

Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks

DRUG

Pembrolizumab

200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed

Trial Locations (7)

Mount Sinai Medical Center, New York

University of Florida Health Sciences Center, Gainesville

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Universitätsklinikum Köln, Cologne

Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz

USC Norris Hospital and Clinics, Los Angeles

Seattle Cancer Care Alliance, Seattle